Core biopsy

Biopsy

Report in 264Hrs

At Home

No Fasting Required

Details

Needle biopsy of deep tissues.

₹666₹951

30% OFF

Core Biopsy - Comprehensive Medical Test Guide

Why is it done?
- Tissue diagnosis - Obtains a cylindrical sample of tissue from suspected abnormal lesions to determine if cells are benign, malignant, or inflammatory
- Cancer detection - Identifies the presence of cancer cells and determines tumor type, grade, and molecular characteristics
- Breast lesion evaluation - Evaluates palpable masses, mammographic abnormalities, or ultrasound-detected lesions in the breast
- Lung nodule assessment - Determines the nature of suspicious lung lesions detected on imaging
- Prostate evaluation - Obtains tissue samples to diagnose prostate cancer in patients with elevated PSA or abnormal digital rectal examination
- Lymph node investigation - Assesses enlarged or abnormal lymph nodes to diagnose lymphoma, metastatic disease, or infection
- Other tissue sampling - Evaluates suspicious lesions in liver, kidney, pancreas, thyroid, bone, and other accessible organs
Normal Range
- Normal result - Absence of malignant cells; benign tissue characteristics with normal histology (no cancer, infection, or significant inflammation)
- Benign findings - Results show non-cancerous tissue such as fibroadenoma (breast), hyperplasia, cysts, or inflammatory conditions
- Negative for malignancy - Pathology report states "negative for malignancy" or "benign" indicating no cancer cells detected
- Adequate tissue sample - Biopsy contains sufficient tissue for accurate diagnosis and analysis
- Interpretation - Results are reported as histopathology findings with specific diagnosis based on microscopic examination and immunohistochemistry when needed
Interpretation
- Positive for malignancy - Cancer cells are present; report includes cancer type (adenocarcinoma, squamous cell carcinoma, etc.), grade (differentiation level), and stage information to guide treatment planning
- Atypia or dysplasia - Cells show abnormal features but do not meet criteria for cancer; indicates increased risk and may require close monitoring, repeat biopsy, or prophylactic treatment depending on severity
- Atypical findings - Uncertain classification between benign and malignant; may include findings such as atypical intraductal proliferation (AIP) in breast; often requires surgical excision or close follow-up
- Benign findings - Non-cancerous tissue; includes specific diagnoses such as fibroadenoma, lipoma, fibrocystic changes, benign prostatic hyperplasia, or inflammatory conditions; typically requires no further intervention
- Infection or inflammation - Presence of bacteria, fungi, or inflammatory markers; indicates infectious process or chronic inflammation requiring appropriate antimicrobial or anti-inflammatory therapy
- Molecular testing results - Additional testing may show specific mutations (EGFR, ALK in lung cancer), HER2 status (breast cancer), hormone receptor positivity, or microsatellite instability; guides targeted therapy selection
- Insufficient tissue sample - Sample does not contain adequate tissue for diagnosis; repeat biopsy or different sampling method may be required
Associated Organs
- Breast tissue - Evaluates palpable masses and mammographic findings; diagnoses invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ (DCIS), and benign lesions
- Lung tissue - Assesses pulmonary nodules and masses; diagnoses lung cancer (adenocarcinoma, squamous cell carcinoma, small cell carcinoma), tuberculosis, fungal infections, and sarcoidosis
- Prostate gland - Evaluates elevated PSA or abnormal rectal examination findings; diagnoses prostate cancer and determines Gleason score for grading and prognosis
- Lymph nodes - Evaluates enlargement from any cause; diagnoses lymphoma, metastatic cancer, tuberculosis, reactive hyperplasia, and other lymphoid disorders
- Liver tissue - Assesses liver lesions and masses; diagnoses hepatocellular carcinoma, metastatic disease, cirrhosis, hepatitis, and other liver pathology
- Thyroid gland - Evaluates thyroid nodules; diagnoses papillary carcinoma, follicular carcinoma, medullary carcinoma, and benign nodular disease; assists in risk stratification using Bethesda classification
- Kidney and urinary tract - Assesses renal masses and bladder lesions; diagnoses renal cell carcinoma, urothelial cancer, and inflammatory conditions
- Pancreas - Evaluates pancreatic masses; diagnoses adenocarcinoma and other malignancies; essential for treatment planning
- Bone and soft tissue - Assesses bone lesions and soft tissue masses; diagnoses primary bone malignancies, osteomyelitis, and other pathology
Follow-up Tests
- Immunohistochemistry (IHC) - Antibody-based testing to determine cancer type, hormone receptor status (ER/PR), HER2 status, and other markers to guide treatment decisions
- Molecular testing and genetic analysis - FISH, PCR, or next-generation sequencing (NGS) for specific mutations (EGFR, ALK, KRAS, BRCA, etc.) to identify targeted therapy options and prognosis
- Flow cytometry - Used for lymph node and hematologic samples to characterize cell populations and diagnose lymphomas and leukemias
- Repeat biopsy - May be recommended if initial sample is inadequate, results are ambiguous, or atypical findings require clarification with surgical excision
- Imaging follow-up - Additional CT, MRI, or ultrasound to assess for metastatic disease, recurrence, or monitor benign lesions on benign results
- Surgical consultation - Required for cancer diagnosis to determine surgical resection, reconstruction, and staging procedures
- Oncology consultation - Essential for cancer diagnosis to plan chemotherapy, radiation therapy, immunotherapy, or targeted treatment based on biopsy findings
- Clinical follow-up imaging - Regular surveillance imaging (every 3-6 months initially, then longer intervals) based on diagnosis and treatment response
- Staging studies - PET scan, chest/abdomen/pelvis CT, or bone scan to identify metastatic disease and determine TNM staging for treatment and prognosis
Fasting Required?
- Fasting: Generally NOT required
- Patient preparation - Patients should inform their physician of any allergies, bleeding disorders, or medications that affect coagulation prior to the procedure
- Medication adjustments - Anticoagulants (warfarin, apixaban, dabigatran) and antiplatelet agents (aspirin, clopidogrel) should typically be discontinued 5-7 days before the procedure; NSAIDs should be avoided 3-5 days prior
- Site-specific preparation - Breast biopsy may require routine fasting if sedation planned; lung biopsy typically requires NPO status; prostate biopsy may require bowel preparation with enemas
- Imaging coordination - Ultrasound-guided biopsies do not require special preparation; CT and fluoroscopy-guided procedures may have specific instructions from the radiology department
- Post-procedure instructions - Patients should arrange for transportation as sedation may be used; avoid strenuous activity for 24-48 hours; monitor for bleeding, infection, or severe pain at biopsy site

How our test process works!